India’s COVID-19 tally at 1.046 crore; active cases highest in Kerala

India’s COVID-19 tally at 1.046 crore; active cases highest in Kerala

India reported 16,311 new COVID-19 cases and 161 deaths in the last 24 hours, the Ministry of Health and Family Welfare (MoHFW) said on Monday. With the addition of fresh infections, the overall cases in the country reached 1,04,66,595 including 2,22,526 active cases. After 19,299 discharges in the last 24 hours, the cumulative recoveries reached 1,00,92,909. The death toll climbed to 1,51,160.

The number of active cases is the highest in Kerala at 64,179 as of now, which is followed by Maharashtra with 54,179 incidences.

Kerala reported 4545 new COVID-19 cases and 4659 recoveries on Sunday. The total recoveries have reached 7,43,467, the state health department said. The death toll in the state has reached 3,303 after recording 23 deaths on Sunday.

Maharashtra reported 3558 new COVID-19 cases, 2302 discharges and 34 deaths on Sunday.
The total case tally has now reached 19,69,114. The total death toll has climbed to 50,061. The cumulative recoveries now stand at 18,63,702.

The state’s recovery rate is 94.65%, while the case fatality rate stands at 2.54%. “Of 1,34,01,170 laboratory samples tested thus far, 19,69,114 have returned positive, with over 63,000 samples being tested in the last 24 hours,” said State Surveillance Officer Dr Pradeep Awate.

Currently, a total of 2,34,845 people across the state are in home quarantine and 2,453 are in institutional quarantine facilities.

The death toll in West Bengal rose to 9,941 with 19 deaths recorded on Sunday. The state reported 823 new COVID-19 cases, taking the total case tally to 5,60,709. The number of active infections stands at 7,881. The state tested 35,123 samples in the last 24 hours and the percentage of positive cases out of the samples tested has dropped to 7.53.

Meanwhile, the MoHFW has announced that the coronavirus vaccination drive in the country will begin from January 16.

The COVID-19 vaccines of Serum Institute of India and Bharat Biotech were granted permission for restricted use in an emergency situation by the Drugs Controller General of India (DCGI).